Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Content 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Article Posted: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
At a time when many investors are rotating out of speculative penny stocks, others still embrace the risk-reward dynamic. Stocks trading under $5 carry elevated risk: many are unprofitable, and some generate little or no revenue. In almost every case these are small-cap companies, which have been beaten up over the past several years. Even though the Russell 2000 shows some signs of recovery, broader small-cap strength remains uneven. That could change in 2026 if the economic outlook continues to improve, at which point money may flow back into speculative names. As with any part of the market, though, quality matters. One way to filter for quality is to look for stocks with positive analyst sentiment. That's true for these three names. Each lets investors establish a meaningful position with a modest outlay while still offering potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be among the winners in 2026, but so far that's not the case for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a "super app" that combines technology, e-commerce and fintech services. One reason for the pullback is its proposed merger with Indonesian ride-hailing rival GoTo. The deal isn't final and could face significant legislative changes in Indonesia that may limit the company's earnings potential there. The company also came slightly short on the top line in its Q4 2025 earnings report. However, revenue grew 19% year-over-year, and this marked the company's first full year of profitability. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains bullish. GRAB stock has a consensus price target of $6.47, which is roughly 54% above the current price. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector, where risk and reward can both be large. One company to watch is Vaxart Inc. (OTCMKTS: VXRT), the only firm on this list that meets the classic definition of a penny stock — trading just over $0.60 per share at the time of writing. VXRT doesn't enjoy heavy analyst coverage, but the one analyst who rated it in the past 12 months gave a Buy with a $2 price target. Limited coverage is common for clinical-stage biotech companies like Vaxart, since all of its candidates are still in trials. The potential upside is straightforward: Vaxart is developing oral vaccines targeting influenza, norovirus and COVID-19. In addition to convenience and removing needle-related fear, the company says its platform can induce a broader immune response and potentially broader protection. Institutional ownership is roughly 18%, but in dollar volume inflows outnumber outflows nearly 10:1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% year-to-date in 2026, but over the past 12 months the stock is up more than 66%. That suggests the recent decline is a pullback amid investor aversion to unprofitable companies. In ThredUp's case, add the caveat "yet." The company operates an online consignment and thrift platform that is gaining traction with Gen-Z consumers — revenue rose 12.5% year-over-year in its most recent quarter. ThredUp cites a GlobalData 2025 market survey forecasting the U.S. secondhand market's gross merchandise value would grow at a 9% compound annual growth rate through 2029. Institutions own about 89% of TDUP. In dollar terms, buying has outpaced selling roughly 2:1, and buyers outnumber sellers about 3:1. However, short interest is around 17%, which can add short-term volatility. The consensus price target from six analysts is $12.50, which would be more than a 190% increase from the stock's price at the time of writing.
| 
